S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
This Tech Stock Could be the Next Amazon (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
This Tech Stock Could be the Next Amazon (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
This Tech Stock Could be the Next Amazon (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
This Tech Stock Could be the Next Amazon (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
This Tech Stock Could be the Next Amazon (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
This Tech Stock Could be the Next Amazon (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
This Tech Stock Could be the Next Amazon (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
This Tech Stock Could be the Next Amazon (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
This Tech Stock Could be the Next Amazon (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
This Tech Stock Could be the Next Amazon (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
This Tech Stock Could be the Next Amazon (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
This Tech Stock Could be the Next Amazon (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
NASDAQ:OTIC

Otonomy - OTIC Stock Forecast, Price & News

$0.11
0.00 (0.00%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.11
$0.12
50-Day Range
$0.10
$0.12
52-Week Range
$0.06
$2.54
Volume
580,884 shs
Average Volume
407,938 shs
Market Capitalization
$7.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25

OTIC stock logo

About Otonomy (NASDAQ:OTIC) Stock

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Stock News Headlines

Otonomy (NASDAQ:OTIC) Now Covered by StockNews.com
Did You See These Trend Reversals?
Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. pixel
Otonomy, Inc.: Otonomy Provides Corporate Update
Otonomy Provides Corporate Update
Why Is Otonomy (OTIC) Stock Up 97% Today?
Did You See These Trend Reversals?
Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. pixel
See More Headlines
Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Company Calendar

Last Earnings
11/10/2021
Today
4/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OTIC
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.25
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$0.50
Forecasted Upside/Downside
+2,776.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-51,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$0.97 per share

Miscellaneous

Free Float
67,780,000
Market Cap
$7.74 million
Optionable
Optionable
Beta
1.58

Key Executives

  • Paul E. Cayer
    President, CFO, Secretary & Chief Business Officer
  • Anna Stepannenko
    Vice President -Technical operations
  • Fabrice Piu
    Vice President-Research & Preclinical Development
  • David Skarinsky
    Vice President-Clinical
  • Jeffery J. Anderson
    Vice President-Clinical Sciences













OTIC Stock - Frequently Asked Questions

Should I buy or sell Otonomy stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OTIC, but not buy additional shares or sell existing shares.
View OTIC analyst ratings
or view top-rated stocks.

What is Otonomy's stock price forecast for 2023?

3 analysts have issued 1-year target prices for Otonomy's stock. Their OTIC share price forecasts range from $0.50 to $6.00. On average, they anticipate the company's share price to reach $3.25 in the next twelve months. This suggests a possible upside of 2,776.1% from the stock's current price.
View analysts price targets for OTIC
or view top-rated stocks among Wall Street analysts.

How have OTIC shares performed in 2023?

Otonomy's stock was trading at $0.0871 at the beginning of 2023. Since then, OTIC stock has increased by 29.7% and is now trading at $0.1130.
View the best growth stocks for 2023 here
.

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) announced its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). During the same period in the previous year, the firm earned ($0.22) earnings per share.

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

How do I buy shares of Otonomy?

Shares of OTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $0.11.

How much money does Otonomy make?

Otonomy (NASDAQ:OTIC) has a market capitalization of $7.74 million and generates $130,000.00 in revenue each year. The biopharmaceutical company earns $-51,180,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.otonomy.com. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at ir@otonomy.com, or via fax at 619-291-9190.

This page (NASDAQ:OTIC) was last updated on 4/1/2023 by MarketBeat.com Staff